Author(s): Bodua A, Wdowczyk M, Adamiec R
Abstract Share this page
Abstract Insulin resistance plays an important role in the development of such abnormalities as impaired glucose tolerance, type 2 diabetes, obesity, and hyperlipidemia. The rates of these diseases are increasing and their cardiovascular complications are among the most common causes of death worldwide. The discovery of protein tyrosine phosphatase (PTP-1B) seems to be a milestone in the investigation of insulin signaling transmission. PTP-1B is considered a negative regulator of insulin signaling, mainly through insulin receptor dephosphorylation. In animal model studies (Elchebly et al.) there was a significant increase in insulin sensitivity of PTP-1B knock-out mice. There is also evidence that higher expression of the PTP-1B gene causes insulin resistance in humans. PTP-1B inhibitors could thus be promising drugs for insulin resistance therapy. The object of this review is to present current evidence of PTP-1B's role in the pathophysiology of insulin resistance abnormalities and the potential treatment of these disorders.
This article was published in Postepy Hig Med Dosw (Online)
and referenced in Journal of Clinical & Medical Genomics